logo

$5 And Under

Share SHARE

Imprimis Pharmaceuticals (IMMY) has been rising sharply since the open of trade Thursday and is now up 0.74 at $2.20 with volume at a 6 1/2 month high. The stock has surged to nearly a 2-month high. Imprimis Pharmaceuticals announced this morning that it is making compounded Cyclosporine-based formulations available.

DarioHealth Corp. (DRIO) announced Wednesday morning that it has received the CE Mark for its Lightning-enabled version of the acclaimed Dario Blood Glucose Monitoring System. This will allow consumers to experience DarioHealth on the latest Apple devices. DarioHealth has been rising sharply since...

Recon Technology Ltd. (RCON) announced Monday morning that it has signed a 3-year strategic cooperation agreement with Beijing OriginWater Purification Engineering Technology Co. Recon Technology has spiked sharply to the upside in early trade Monday and is now higher by 0.87 at $1.90 on the highest...

Akers Biosciences Inc. (AKER) has suddenly spiked sharply higher in the last few minutes on increased volume. The stock is now up 0.83 at $1.70. Akers Biosciences has surged to nearly a 5-month high.

Ardelyx Inc. (ARDX) announced after the bell Wednesday that its Phase 3 study of tenapanor, for irritable bowel syndrome with constipation, achieved statistical significance for the primary endpoint and all secondary endpoints. The stock is now up 3.15 on 174K shares Ardelyx traded in a narrow range...

Leading Brands Inc. (LBIX) has been rising steadily since the open of trade Wednesday and is now up 1.27 at $2.45. Trading volume has begun to accelerate in the last 15 minutes. Leading Brands is adding to yesterday's late gains and has surged to a 6-month high.

Shares of Sphere 3D Corp. (ANY) have been climbing sharply since the open of trade Monday. The stock is now up 1.15 at $3.67 on above average volume. Sphere 3D has surged to a 2-week high and is now challenging its 50-day moving average.

Dynasil Corp. Of America (DYSL) announced Wednesday morning that its Xcede Technologies subsidiary has completed most of the required ISO 10993-1 Testing Program for the Xcede Hemostatic Patch. The company is encouraged by the results thus far and expects to start clinical trials in the Netherlands in...

Real Goods Solar (RGSE) announced Wednesday morning that it has entered into an exclusive domestic and international license agreement with The Dow Chemical Company for the POWERHOUSE solar shingles system. Real Goods Solar has gapped open sharply higher this morning and is now up 1.52 at $2.34 with...

Cesca Therapeutics Inc. (KOOL) announced Tuesday morning that the U.S. Patent and Trademark Office has issued a Notice of Allowance regarding its pending application for a patent covering its proprietary method for separating cells. Cesca Therapeutics gapped up at the open Tuesday and rose sharply...

Celsion Corp. (CLSN) presented the final data from its Phase Ib clinical trial, combining GEN-1 with the standard of care, at the American Association of Cancer Research Special Conference. Celsion climbed for the majority of Tuesday's session and finished up by 4.55 at $6.06 on the highest volume...

Cesca Therapeutics Inc. (KOOL) announced Tuesday morning that the U.S. Patent and Trademark Office has issued a Notice of Allowance regarding its pending application for a patent covering its proprietary method for separating cells. Cesca Therapeutics gapped open higher Tuesday and has surged higher...

Axovant Sciences Ltd. (AXON) announced Tuesday morning that its Phase 3 trial of intepirdine, in patients with mild to moderate Alzheimer's disease who were receiving background donepezil therapy, failed to meet its co-primary efficacy endpoints. Axovant Sciences has gapped open dramatically lower...

Versartis Inc. (VSAR) announced after the close Thursday that its Phase 3 study of somavaratan did not meet its primary endpoint. Versartis gapped open dramatically lower Friday, but was range-bound throughout the session. The stock closed down by 18.93 at $2.68 on the highest volume of the year....

Versartis Inc. (VSAR) announced after the close Thursday that its Phase 3 study of somavaratan did not meet its primary endpoint. Versartis has gapped open dramatically lower Friday morning and is now down 18.53 at $3.08 on the highest volume of the year. The stock has plunged to a new low for the year.

Follow RTT